

PB203, A Triple-Target TME Disruptor (PD-L1/VEGF-A/PLGF): Next-generation immuno-oncology solution for pancreatic cancer, paving the way for refractory fibrotic/immune-excluded tumors

Panolos Bioscience Inc.



ONCOLOGY	Preclinical
Product Type	Antibody
Indication	Pancreatic cancer (Gateway to NSCLC, TNBC, and other immune-excluded/fibrotic solid tumors)
Target	PD-L1, VEGF-A, and PLGF (multi-specific, simultaneous)
MoA (Mechanism of Action)	PB203 is a multifunctional protein drug that simultaneously targets VEGF, PLGF, and PD-L1. It blocks angiogenesis via VEGF/PLGF neutralization and curbs desmoplasia caused by PLGF, addressing immune desert in tumor microenvironment. Additionally, it reactivates immune responses against tumor cells by inhibiting the PD-L1 pathway.
Competitiveness	<ul style="list-style-type: none"> • αART® platform-driven multi-specific drug: Simplified manufacturing and ~7× higher productivity than Avastin-based bi-specific antibodies targeting VEGF-A/PD-(L)1 axis. • Single biologic, triple blockade: Cost-effective & target-specific action mechanism reducing systemic side effects and maximizing therapeutic effects • Dual actions on tumor microenvironment by way of VEGF-A/PLGF blocking: Vascular normalization via VEGF-A/PLGF inhibition + anti-fibrotic efficacy through PLGF suppression • KRAS-independent efficacy in pancreatic cancer: Applicable both KRAS wild-type and mutated genotype, showing wider clinical utility
Development Stage	Preclinical
Route of Administration	<ul style="list-style-type: none"> • Intravenous (IV) injection • Subcutaneous (SC) formulation development under active consideration

Any unauthorized distribution or reproduction of this material is strictly prohibited.